Candida glabrata Biofilms: How Far Have We Come?

Area of Science:

• Mycology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Rising incidence of *Candida* species infections, leading to significant morbidity and mortality.
• *Candida glabrata* is a prevalent human pathogen, second only to *Candida albicans*.
• *C. glabrata* exhibits high antifungal drug resistance, lacks hyphae formation, and possesses virulence factors contributing to aggressive infections and recurrent candidiasis, notably through biofilm formation.

Purpose of the Study:

• To review the current knowledge on *Candida glabrata*'s resistance mechanisms.
• To focus on the challenges posed by *C. glabrata* biofilms.
• To explore emerging therapeutic alternatives for controlling *C. glabrata* biofilms.

Main Methods:

• Literature review of scientific articles on *Candida glabrata*.
• Analysis of virulence factors and resistance mechanisms.
• Examination of biofilm formation and antifungal treatment strategies.

Main Results:

• *C. glabrata* biofilms exhibit remarkable resistance to antifungal treatments due to their complex matrix structure.
• The inherent resistance and virulence factors of *C. glabrata* contribute to poor therapeutic responses.
• Existing antifungal drugs show limited efficacy against *C. glabrata* biofilms.

Conclusions:

• *Candida glabrata* poses a significant clinical challenge due to its resistance and biofilm-forming capabilities.
• Novel therapeutic approaches are crucial for effectively managing *C. glabrata* infections, particularly biofilms.
• Further research into alternative treatments is essential to overcome the limitations of current antifungal therapies.